2383O A phase III study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281
K. Fizazi, N.W. Clarke, M. De Santis, Hirotsugu Uemura et autres
fr, gb, de, jp, br, tr, pl, es, cn, au, kr, nl, th, sg, us (code pays fourni par la source)